Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Xenon (XENE – Research Report) today and set a price target of $53.00.

Tempest Therapeutics (TPST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

East Windsor is excited to welcome another pharmaceutical company Rising Pharmaceuticals to join the many other high-tech ...

ONL Therapeutics Inc. is a classic case of a ... arm of New Jersey-headquartered Johnson & Johnson medical devices and pharmaceutical company. The rise of expensive gene therapies could cure ...

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Acadia Pharmaceuticals sold its priority review voucher for $150 million. Haleon named Vistar Media, a location-based ad ...

AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop ...

A Memphis-based company has branched out into an international market with a new licensing agreement. Hera Health Solutions, ...

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic ...